Condition
Graft Rejection
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 6 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
6 shownOPtimal Adult Heart Transplant Immunosuppression With MicroRNA LevelsNCT06939751 · 2025-10-28
RECRUITINGOptimal Pediatric Heart Transplant Immunosuppression With MicroRNAsNCT06532890 · 2025-02-06
RECRUITINGRegenerative Cellular Therapies, Physiology, Pathology and Developmental BiologyNCT02469207 · 2016-01-01
UNKNOWNThymoglobulin in Calcineurin Inhibitor and Steroid Minimization ProtocolNCT00706680 · 2008-02-01
UNKNOWNStudy Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant RecipientsNCT00369382 · 2006-09-01
COMPLETEDStudy of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas TransplantationNCT00331162 · 2005-02-01
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
COMPLETED2
RECRUITING2
UNKNOWN2
Phase mix
PHASE43
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.